Gliadel

Lymphoma, Non-Hodgkin, Glioblastoma, Multiple Myeloma + 9 more
Treatment
20 Active Studies for Gliadel

What is Gliadel

CarmustineThe Generic name of this drug
Treatment SummaryA cell-cycle phase nonspecific alkylating antineoplastic agent is a type of medication used to treat brain tumors and other forms of cancer. This drug has been identified as a possible carcinogen and should be used with caution.
Gliadelis the brand name
image of different drug pills on a surface
Gliadel Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Gliadel
Carmustine
1996
17

Effectiveness

How Gliadel Affects PatientsCarmustine is a medication used to treat brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. It works by attaching itself to DNA and RNA, and can also interfere with certain proteins. It is not the same as other alkylators but has similar effects. Carmustine is usually taken as part of combination therapy with other chemotherapy drugs.
How Gliadel works in the bodyCarmustine stops cells from making new DNA and proteins, which kills them. It does this by forming links between the DNA and RNA of the cell, blocking their ability to make new material. Carmustine also interferes with a specific protein that helps protect the cell, leading to its death.

When to interrupt dosage

The measure of Gliadel is contingent upon the determined condition, such as Glioblastoma, Newly Diagnosed High Grade Glioma (HGG) and Medulloblastomas. The dosage fluctuates depending on the delivery approach featured in the table below.
Condition
Dosage
Administration
Glioblastoma
, 7.7 mg, 100.0 mg, 10.0 mg/mL
, Intracavitary, Wafer, Wafer - Intracavitary, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Intralesional, Wafer - Intralesional, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Metastatic Brain Tumors
, 7.7 mg, 100.0 mg, 10.0 mg/mL
, Intracavitary, Wafer, Wafer - Intracavitary, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Intralesional, Wafer - Intralesional, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Ependymoma
, 7.7 mg, 100.0 mg, 10.0 mg/mL
, Intracavitary, Wafer, Wafer - Intracavitary, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Intralesional, Wafer - Intralesional, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Lymphoma, Non-Hodgkin
, 7.7 mg, 100.0 mg, 10.0 mg/mL
, Intracavitary, Wafer, Wafer - Intracavitary, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Intralesional, Wafer - Intralesional, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Glioblastoma
, 7.7 mg, 100.0 mg, 10.0 mg/mL
, Intracavitary, Wafer, Wafer - Intracavitary, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Intralesional, Wafer - Intralesional, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Multiple Myeloma
, 7.7 mg, 100.0 mg, 10.0 mg/mL
, Intracavitary, Wafer, Wafer - Intracavitary, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Intralesional, Wafer - Intralesional, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Hodgkin Disease
, 7.7 mg, 100.0 mg, 10.0 mg/mL
, Intracavitary, Wafer, Wafer - Intracavitary, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Intralesional, Wafer - Intralesional, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Medulloblastoma
, 7.7 mg, 100.0 mg, 10.0 mg/mL
, Intracavitary, Wafer, Wafer - Intracavitary, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Intralesional, Wafer - Intralesional, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Glioma
, 7.7 mg, 100.0 mg, 10.0 mg/mL
, Intracavitary, Wafer, Wafer - Intracavitary, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Intralesional, Wafer - Intralesional, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Brain Stem Gliomas
, 7.7 mg, 100.0 mg, 10.0 mg/mL
, Intracavitary, Wafer, Wafer - Intracavitary, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Intralesional, Wafer - Intralesional, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Astrocytoma
, 7.7 mg, 100.0 mg, 10.0 mg/mL
, Intracavitary, Wafer, Wafer - Intracavitary, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Intralesional, Wafer - Intralesional, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Mycosis Fungoides
, 7.7 mg, 100.0 mg, 10.0 mg/mL
, Intracavitary, Wafer, Wafer - Intracavitary, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Intralesional, Wafer - Intralesional, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous

Warnings

Gliadel Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Carmustine may interact with Pulse Frequency
There are 20 known major drug interactions with Gliadel.
Common Gliadel Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Carmustine is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Carmustine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abetimus
Major
The risk or severity of adverse effects can be increased when Carmustine is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Carmustine is combined with Acteoside.
Aldosterone
Major
The risk or severity of adverse effects can be increased when Carmustine is combined with Aldosterone.
Gliadel Toxicity & Overdose RiskThe toxic dose of the drug in rats and mice is 20mg/kg and 45mg/kg. Common side effects include low white blood cell count, low platelet count, and nausea. Serious toxicity includes lung scarring (20-0%) and bone marrow damage.
image of a doctor in a lab doing drug, clinical research

Gliadel Novel Uses: Which Conditions Have a Clinical Trial Featuring Gliadel?

166 active studies are exploring the efficacy of Gliadel in the management of Newly Diagnosed High Grade Glioma (HGG), Hodgkin Disease, Non-Hodgkin Lymphoma and other conditions.
Condition
Clinical Trials
Trial Phases
Medulloblastoma
0 Actively Recruiting
Metastatic Brain Tumors
55 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Early Phase 1, Phase 4
Hodgkin Disease
2 Actively Recruiting
Phase 2, Phase 1
Lymphoma, Non-Hodgkin
0 Actively Recruiting
Glioma
0 Actively Recruiting
Astrocytoma
0 Actively Recruiting
Ependymoma
0 Actively Recruiting
Glioblastoma
2 Actively Recruiting
Phase 1
Mycosis Fungoides
0 Actively Recruiting
Brain Stem Gliomas
1 Actively Recruiting
Phase 2
Multiple Myeloma
6 Actively Recruiting
Phase 2, Phase 1, Not Applicable
Glioblastoma
60 Actively Recruiting
Phase 1, Phase 2, Early Phase 1, Not Applicable, Phase 3

Gliadel Reviews: What are patients saying about Gliadel?

5Patient Review
10/14/2021
Gliadel for Malignant Brain Tumor Glioblastoma
I was diagnosed with a Glioblastma brain tumor 24 years ago and given a gliadel wafer. Thanks to the treatment and my faith, I'm still alive today. My neurologist calls me a miracle!
3.7Patient Review
12/30/2010
Gliadel for Malignant Brain Tumor Glioblastoma
My wife had a terminal illness and was only given 1-2 years to live. However, she went into remission and lived for an additional four years. I'm not sure if it was the wafers or a combination of the wafers with radiation, but we were able to spend more time together as a family that we otherwise would have missed out on.
3Patient Review
3/12/2013
Gliadel for Malignant Brain Tumor Glioblastoma
My wife has gbm and had 8 wafers implanted 2 months ago. She is now having severe bouts of paranoia and delusion. Its hard to say for sure if they're caused by the wafers but she didn't have these symptoms after her tumor removal surgery, radiation and chemo in the three months prior.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about gliadel

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long do Gliadel wafers last?

"The wafers release a chemotherapy drug called carmustine directly to the surrounding cells. This process usually takes around 2 to 3 weeks. As the wafers release the drug, they dissolve. This means there is no need to remove them."

Answered by AI

Is Gliadel FDA approved?

"In 1997, the FDA approved Gliadel wafers for the treatment of recurrent GBM. In 2003, they approved it for the treatment of newly diagnosed HGG (World Health Organization (WHO) grade III and grade IV glioma)."

Answered by AI

How much does Gliadel cost?

"The average cost for the Gliadel implant device 7.7 mg is $35,791 for a supply of 8 devices, depending on the pharmacy you visit. Prices may vary for cash paying customers and those with insurance plans."

Answered by AI

What is Gliadel used for?

"The Gliadel wafer contains the chemotherapy drug carmustine. It is inserted by a neurosurgeon during surgery to remove a brain tumor. This treatment is for a brain tumor called glioblastoma multiforme in adults."

Answered by AI

Clinical Trials for Gliadel

Image of University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center in Cleveland, United States.

Whole Brain Radiotherapy for Brain Cancer

18+
All Sexes
Cleveland, OH
Participants in this research study have cancer that has spread to their brain, called brain metastases. One treatment for this type of cancer is called whole brain radiotherapy that stays away from a specific neurocognitive substructure, called the hippocampus, combined with medication to preserve cognitive function. This study compares that approach to another approach of whole brain radiotherapy that stays away from additional structures that are thought to have a role in cognitive function. Researchers want to see if there is a difference in the preservation of cognitive function between these two approaches.
Phase 2
Waitlist Available
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer CenterHaley Perlow, MD
Image of Washington University School of Medicine in St Louis, United States.

NT-I7 + CAR-T Therapy for Multiple Myeloma

18+
All Sexes
St Louis, MO
CAR-T cell therapy is an emerging treatment modality in relapsed and refractory multiple myeloma (MM). CAR-T therapy in MM relies on directing autologous T-cells to detect and clear myeloma cells expressing B-cell Maturation Antigen (BCMA). While BCMA CAR-T cell-treated patients achieve an excellent overall response rate, their response is often not durable. NT-I7 promotes CAR-T cell expansion and efficacy in pre-clinical lymphoma models. In patients receiving CD19-directed CAR-T therapy for lymphoma, NT-I7 augmented CAR-T expansion while being safe and tolerable. The impact of NT-I7 on BCMA CAR-T cells in multiple myeloma is unknown. This is a two-arm, double blind, placebo-controlled, randomized, single-site phase Ib study testing the safety and toxicity of adding NT-I7 to BCMA CAR-T therapy in patients with relapsed and refractory multiple myeloma. The hypothesis is that NT-I7 will promote CAR-T expansion and persistence which will enhance clearance of MM, while maintaining a favorable safety and toxicity profile. Patients receiving standard of care BCMA CAR-T (Cilta-cel) will be randomized to either NT-I7 or placebo. Correlative studies will evaluate CAR-T cell expansion, persistence, immune-phenotype, function and correlate with clinical outcomes.
Phase 1
Waitlist Available
Washington University School of MedicineMichael Slade, M.D., M.S.C.INeoImmuneTech
Image of Mayo Clinic in Phoenix, United States.

MT-125 for Glioblastoma

18+
All Sexes
Phoenix, AZ
The purpose of the study is to determine the recommended dose and further understand the safety of MT-125 in participants who have been diagnosed with glioblastoma, a primary brain tumor, when administered in combination with your standard of care treatment. Initially, participants with newly diagnosed glioblastoma will be given different doses of MT-125 in combination with radiotherapy (RT) with the goal of identifying the highest tolerated dose. Up to 36 people with glioblastoma who are at least18 years old are being invited to join this study. MT-125 is a type of study treatment which acts on cancer cells in the brain to destroy them. It will be administered on the same day as your standard of care radiotherapy because it is also designed to help radiotherapy work better. However, this is the first time MT-125 will be studied in humans. Therefore, the use is considered investigational. If you would like more details about MT-125 in glioblastoma participants, please ask the Study Doctor. You will be among the first participants with glioblastoma to receive this study treatment. Its safety and effectiveness have not yet been established in humans. Thus, we do not know whether it will work for you. Your condition may improve, may get worse, or there may be no change. The selected participant population-individuals newly diagnosed with histologically and/or molecularly confirmed IDH wild-type, MGMT-unmethylated glioblastoma-represents those least likely to experience safety concerns or adverse events related to the study treatment, and most likely to derive therapeutic benefit. There are certain tests/questions you must complete to find out if you meet the requirements to be in the study. If you do not meet these requirements, you cannot take part in the study. If this happens, you can talk to your Study Doctor about other options.
Phase 1
Waitlist Available
Mayo Clinic (+2 Sites)Myosin Therapeutics Inc.
Have you considered Gliadel clinical trials? We made a collection of clinical trials featuring Gliadel, we think they might fit your search criteria.Go to Trials
Image of Brigham and Women's Hospital / Dana-Farber Cancer Institute in Boston, United States.

Stereotactic Radiation for Brain Cancer

18+
All Sexes
Boston, MA
The goal of this study is to evaluate the feasibility and effectiveness of same-day radiation planning and treatment. The study will shorten the time interval between radiation planning (radiation mapping) and radiation treatment. The intent of this shorter time interval is to increase the likelihood that the brain metastases being treated remain fully within the high-dose radiation fields. Participants will be randomized to receive brain-directed stereotactic radiation with a 1mm margin or 0mm margin, have their simulation/radiation planning imaging on the same day that brain-directed stereotactic radiation is delivered, and have repeat simulation/radiation planning scans during the course of treatment if more than 2-3 days have elapsed since the most recent scans.
Phase 2
Waitlist Available
Brigham and Women's Hospital / Dana-Farber Cancer InstituteAyal A Aizer, MD, MHSVarian, a Siemens Healthineers Company
Have you considered Gliadel clinical trials? We made a collection of clinical trials featuring Gliadel, we think they might fit your search criteria.Go to Trials
Image of London Health Sciences Centre in London, Canada.

Temozolomide Timing for Glioblastoma

18+
All Sexes
London, Canada
The body's biological functions follow a circadian rhythm, meaning that individual biological functions in the body change over a 24-hour cycle. There is evidence suggesting that the body and cancer cells may react differently to anti-cancer treatment based on the time of day they are exposed. In fact, researchers have already found that giving anti-cancer treatments at a particular time of the day works better in rectal and ovarian cancer. Temozolomide (TMZ) is a chemotherapy pill/capsule commonly given to patients with newly diagnosed glioblastoma after brain surgery and radiation treatment. However, there is no current standard for what time of day TMZ should be taken for the treatment of glioblastoma. In the current study, participants are randomly placed in one of two groups: a morning group and an evening group. Based on this group placement, participants are instructed to either take their TMZ in the morning or in the evening and record the date and time they take their TMZ in a pill diary. Participants will wear a wrist actigraphy device for the first cycle of TMZ. The primary goal of the study is to understand if taking TMZ at a prescribed time of day (morning/evening) is feasible in adults with glioblastoma. This is a pilot trial, and the investigators hypothesize that it will be feasible for glioblastoma patients to take TMZ at the prescribed time of day. The secondary goals of this study are to evaluate participant recruitment, safety, health-related quality of life, biological timing of TMZ delivery, and changes in condition over time. This pilot study will help investigators plan for a larger, pragmatic randomized clinical trial in the future.
Recruiting
Has No Placebo
London Health Sciences Centre (+1 Sites)Terry Ng, MD
Image of Brigham and Women's Hospital in Boston, United States.

Intensified Radiation Therapy for Brain Cancer

65+
All Sexes
Boston, MA
Glioblastoma (GBM) is an aggressive malignancy of the central nervous system. Older adults with GBM have a unique constellation of medical, psychosocial, and supportive care needs. To address these challenges, prior work has evaluated the feasibility of hypofractionation, a treatment approach delivering fewer, larger radiation dosages over a shorter time period. Common hypofractionated regimens deliver a lower biologically equivalent radiation dose than the conventional regimens used for younger adults. Whether dose escalated hypofractionation can further improve outcomes in older adults remains unclear. This will be a hybrid randomized control trial comparing the efficacy and safety of dose-escalated and standard hypofractionated radiotherapy among older adults with newly-diagnosed glioblastoma compared to standard three-week course. This research study involves the administration of radiation therapy. Radiation will either be delivered at the standard daily dose or at an increased daily dose over a three weeks course of radiation treatment. Research study procedures will include a screening evaluation to assess eligibility, as well as clinical visits for radiation delivery and to assess symptoms during treatment and at scheduled follow-up times. Participants will be randomly assigned to one of the two arms of the trial: 1. Standard hypofractionated radiation over 3 weeks 2. Dose-escalated hypofractionated radiation over 3 weeks
Phase 2
Recruiting
Brigham and Women's Hospital (+2 Sites)
Image of Duke University Health System in Durham, United States.

Selinexor + Antibody for Multiple Myeloma

18+
All Sexes
Durham, NC
The primary objectives of this study are to determine the safety of single agent Selinexor given with commercial bispecific antibody therapy in patients with Relapsed/Refractory Multiple Myeloma (RRMM) and to determine the MRD negativity rate at 10-5 at 12 months post bispecific antibody therapy. The investigators will enroll 27 patients with RRMM who are receiving commercial bispecific antibody therapy. Patients will be on treatment for 12 months or until disease progression, and will be followed for 24 months. Study assessments include completing a drug diary, having a safety check in call, and have history, clinical assessments, and labs taken. Twenty-seven patients will provide 80% power in a one-sample chi square test for a proportion assuming that the rate of negative MRD at 10-5 at 12 months post bispecific antibody therapy is 25% in historical control and 50% in the SEL+bispecific antibody experimental treatment group, under a one-sided 5% significance level.
Phase 2
Recruiting
Duke University Health SystemYubin Kang, MD
Image of Arizona Cancer Center at UMC North/University Medical Center in Tucson, United States.

Tarlatamab + Radiation for Cancer

18 - 99
All Sexes
Tucson, AZ
Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 patients demonstrating safety of treatment, allow for expansion to cranial sites of disease (N=6-10) with continued enrollment in main cohort II) If toxicity criteria is not met in concurrent RT tarlatamab cohort, we will continue with sequential RT, either A) delivered within 7 days prior to cycle 1 day 1, or B) delivered during cycle 1 -2 but with pre- and post-RT washout of 7 days with no drug during RT, to examine safety in a temporally spaced setting. III) If sequential tarlatamab and radiation is not deemed safe, we would allow for continued enrollment to assess efficacy of drug sans radiation treatment, enriching for tumors not of small cell lung cancer histology and allowing for patients without sites amenable to RT. A nested phase II study will attempt to assess for ORR and safety of study intervention amongst tumors not of small cell lung cancer histology.
Phase 1 & 2
Recruiting
Arizona Cancer Center at UMC North/University Medical CenterCharles Hsu, MDAmgen
Have you considered Gliadel clinical trials? We made a collection of clinical trials featuring Gliadel, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security